National surveillance of emergency department visits for outpatient adverse drug events

被引:612
|
作者
Budnitz, Daniel S.
Pollock, Daniel A.
Weidenbach, Kelly N.
Mendelsohn, Aaron B.
Schroeder, Thomas J.
Annest, Joseph L.
机构
[1] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis, Coordinating Ctr Infect Dis, Atlanta, GA 30333 USA
[2] Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA
[3] US FDA, Off Drug Safety, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA
[4] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA
[5] US Consumer Prod Safety Commiss, Bethesda, MD USA
来源
关键词
D O I
10.1001/jama.296.15.1858
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Adverse drug events are common and often preventable causes of medical injuries. However, timely, nationally representative information on outpatient adverse drug events is limited. Objective To describe the frequency and characteristics of adverse drug events that lead to emergency department visits in the United States. Design, Setting, and Participants Active surveillance from January 1, 2004, through December 31, 2005, through the National Electronic Injury Surveillance System Cooperative Adverse Drug Event Surveillance project. Main Outcome Measures National estimates of the numbers, population rates, and severity (measured by hospitalization) of individuals with adverse drug events treated in emergency departments. Results Over the 2-year study period, 21 298 adverse drug event cases were reported, producing weighted annual estimates of 701 547 individuals (95% confidence interval [CI], 509 642-893 452) or 2.4 individuals per 1000 population(95% CI, 1.7-3.0) treated in emergency departments. Of these cases, 3487 individuals required hospitalization (annual estimate, 117 318 [16.7%]; 95% CI, 13.1%-20.3%). Adverse drug events accounted for 2.5% (95% CI, 2.0%-3.1%) of estimated emergency department visits for all unintentional injuries and 6.7% (95% CI, 4.7%-8.7%) of those leading to hospitalization and accounted for 0.6% of estimated emergency department visits for all causes. Individuals aged 65 years or older were more likely than younger individuals to sustain adverse drug events (annual estimate, 4.9 vs 2.0 per 1000; rate ratio [RR], 2.4; 95% CI, 1.8-3.0) and more likely to require hospitalization (annual estimate, 1.6 vs 0.23 per 1000; RR, 6.8; 95% CI, 4.3-9.2). Drugs for which regular outpatient monitoring is used to prevent acute toxicity accounted for 41.5% of estimated hospitalizations overall (1381 cases; 95% CI, 30.9%-52.1%) and 54.4% of estimated hospitalizations among individuals aged 65 years or older (829 cases; 95% CI, 45.0%-63.7%). Conclusions Adverse drug events among outpatients that lead to emergency department visits are an important cause of morbidity in the United States, particularly among individuals aged 65 years or older. Ongoing, population-based surveillance can help monitor these events and target prevention strategies.
引用
收藏
页码:1858 / 1866
页数:9
相关论文
共 50 条
  • [1] National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents
    Cohen, Adam L.
    Budnitz, Daniel S.
    Weidenbach, Kelly N.
    Jernigan, Daniel B.
    Schroeder, Thomas J.
    Shehab, Nadine
    Pollock, Daniel A.
    [J]. JOURNAL OF PEDIATRICS, 2008, 152 (03): : 416 - 421
  • [2] Emergency department visits for outpatient adverse drug events: Demonstration for a national surveillance system
    Budnitz, DS
    Pollock, DA
    Mendelsohn, AB
    Weidenbach, KN
    McDonald, AK
    Annest, JL
    [J]. ANNALS OF EMERGENCY MEDICINE, 2005, 45 (02) : 197 - 206
  • [3] Regional surveillance of emergency-department visits for outpatient adverse drug events
    A. Capuano
    A. Irpino
    M. Gallo
    L. Ferrante
    M. L. Illiano
    B. Rinaldi
    A. Filippelli
    F. Rossi
    [J]. European Journal of Clinical Pharmacology, 2009, 65
  • [4] Regional surveillance of emergency-department visits for outpatient adverse drug events
    Capuano, A.
    Irpino, A.
    Gallo, M.
    Ferrante, L.
    Illiano, M. L.
    Rinaldi, B.
    Filippelli, A.
    Rossi, F.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (07) : 721 - 728
  • [5] National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents (vol 152, pg 416, 2008)
    Cohen
    [J]. JOURNAL OF PEDIATRICS, 2008, 152 (06): : 893 - 893
  • [6] US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014
    Shehab, Nadine
    Lovegrove, Maribeth C.
    Geller, Andrew I.
    Rose, Kathleen O.
    Weidle, Nina J.
    Budnitz, Daniel S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (20): : 2115 - 2125
  • [8] Adverse Drug Events in Adult Patients Leading to Emergency Department Visits
    Sikdar, Khokan C.
    Alaghehbandan, Reza
    MacDonald, Don
    Barrett, Brendan
    Collins, Kayla D.
    Donnan, Jennifer
    Gadag, Veeresh
    [J]. ANNALS OF PHARMACOTHERAPY, 2010, 44 (04) : 641 - 649
  • [9] Emergency Department Visits by Children and Adolescents for Antipsychotic Drug Adverse Events
    Hampton, Lee M.
    Daubresse, Matthew
    Chang, Hsien-Yen
    Alexander, G. Caleb
    Budnitz, Daniel S.
    [J]. JAMA PSYCHIATRY, 2015, 72 (03) : 292 - 294
  • [10] Suspected adverse drug events requiring emergency department visits or hospital admissions
    R. Raschetti
    M. Morgutti
    F. Menniti-Ippolito
    A. Belisari
    A. Rossignoli
    P. Longhini
    C. La Guidara
    [J]. European Journal of Clinical Pharmacology, 1999, 54 : 959 - 963